INTRODUCTION

Glioblastoma (GBM) is the most common and deadly form of primary brain tumors in adults. The current standard—aggressive therapy consisting of maximal surgical resection followed by concurrent radiotherapy (RT), temozolomide (TMZ) chemotherapy, and adjuvant TMZ—has shown a median survival of only 14.6 months (1-3). Although GBMs generally have a very poor prognosis, there are clearly cohorts of patients that benefit from specific therapies. Thus, there is great interest in identifying risk factors and biomarkers for predicting response to therapy beforehand. Patient age at diagnosis, neurological performance status, extent of surgical resection, radiographic composition of the tumor, tumor volume and location, isocitrate dehydrogenase 1 mutation status, gene expression subtype, and O6-methylguanine methyltransferase promoter methylation are commonly assessed prognostic characteristics for GBM (4-12).

The use of imaging features to phenotype tumors and to predict therapeutic response is an attractive option compared with more invasive approaches based on tissue-derived biomarkers. By noninvasively characterizing the composition of the tumor microenvironment, features associated with particular response patterns can be identified that lead to the potential for patient cohort enrichment for use in clinical trials. We recently showed that the apparent diffusion coefficient (ADC) characteristics measured using diffusion magnetic resonance imaging (MRI) techniques can be used to predict both progression-free survival (PFS) and overall survival (OS) in GBM (13).

The standard of care for newly diagnosed glioblastoma (GBM) is surgery first, radiotherapy (RT) with concurrent temozolomide (TMZ) second, and adjuvant TMZ last. We hypothesized patients with low diffusivity measured using apparent diffusion coefficient (ADC) histogram analysis evaluated after RT + TMZ and before adjuvant TMZ would have a significantly shorter progression-free survival (PFS) and overall survival (OS). To test this hypothesis, we evaluated 120 patients with newly diagnosed GBM receiving RT + TMZ followed by adjuvant TMZ. Magnetic resonance imaging was performed after completing RT + TMZ and before initiating adjuvant TMZ. A double Gaussian mixed model was used to describe the ADC histograms within the enhancing tumor, where ADC_L and ADC_H were defined as the mean ADC value of the lower and higher Gaussian distribution, respectively. An ADC_L value of 1.0 \( \mu \text{m}^2/\text{ms} \) and ADC_H value of 1.6 \( \mu \text{m}^2/\text{ms} \) were used to stratify patients into high- and low-risk categories. Results suggested that patients with a low ADC_L had a significantly shorter PFS (Cox hazard ratio = 0.12, \( P = 0.0006 \)). OS was significantly shorter with low ADC_L tumors, showing a median OS of 407 versus 644 days (Cox hazard ratio = 0.31, \( P = 0.047 \)). ADC_H did not predict PFS or OS when accounting for age and ADC_L. In summary, after completing RT + TMZ, newly diagnosed glioblastoma patients with a low ADC_L are likely to progress and die earlier than patients with a higher ADC_L. ADC histogram analysis may be useful for patient-risk stratification after completing RT + TMZ.

KEY WORDS: glioblastoma, ADC histogram analysis, diffusion MRI

ABBREVIATIONS: Apparent diffusion coefficient (ADC), area under the curve (AUC), confidence interval (CI), glioblastoma multiforme (GBM), hazard ratio (HR), magnetic resonance imaging (MRI), overall survival (OS), progression-free survival (PFS), receiver operating characteristic (ROC), radiation therapy (RT), temozolomide (TMZ)
sion-free survival (PFS) and overall survival (OS) in GBM patients treated with bevacizumab at recurrence (13-15). Specifically, results in both single and multicenter trials have shown high ADC measurements within the contrast-enhancing tumor regions predict a favorable response to bevacizumab treatment at recurrence as indicated by a longer PFS and OS, whereas patients with low ADC measurements have a significantly shorter PFS and OS. It is important to note that results have also suggested that the prognostic capabilities of ADC measurements may be specific to bevacizumab therapy at recurrence, because no difference in PFS or OS were noted in bevacizumab-naive patients treated with chemotherapy at recurrence (13). However, it is conceivable that ADC measurements may also be prognostic when used to evaluate the phase of adjuvant TMZ before the first recurrence, because various studies have suggested a general increase in ADC after successful RT + TMZ (16-21).

In this study, we examined a cohort of 120 patients with a newly diagnosed GBM that underwent tumor resection followed by RT + TMZ. We then evaluated the diffusion MRI characteristics within the tumor 4 weeks after completing RT + TMZ—just before starting the adjuvant phase of TMZ therapy. We hypothesized that high ADC measurements within contrast-enhancing voxels after completing RT + TMZ would indicate a longer PFS and OS.

**METHODOLOGY**

**Patient Characteristics**

All patients participating in this study signed institutional review board-approved informed consent. Data acquisition was performed in compliance with all applicable Health Insurance Portability and Accountability Act regulations. Patients were retrospectively selected from our institution’s neuro-oncology database. Initially, a total of 169 patients who met the following criteria were selected: (1) pathology-confirmed glioblastoma, (2) treatment with standard external beam radiotherapy and concurrent TMZ followed by adjuvant TMZ, and (3) MRI scans obtained after surgical resection and within 4 weeks after RT + TMZ—just before the adjuvant phase of TMZ. The average age for this population was 58.4 years (±11-year SD), the average Karnofsky performance status score was 86 (±10 SEM), and 57% of the patients were male (97/169). In total, 70 patients had a gross total resection at the time of initial surgery, 73 had a subtotal resection, and 26 had only a biopsy before radiochemotherapy.

Of all patients enrolled, 120 had good-quality diffusion-weighted images and were included in the final analyses for this study. Exclusions were based on gross geometric distortions or low signal-to-noise ratios in the raw diffusion-weighted imaging datasets or patients with a contrast-enhancing tumor less than 0.1 cc as seen on the first MRI scan after RT + TMZ. These follow-up scans were obtained approximately 10 weeks from the time of treatment initiation (mean = 75 ± 2.6-day SEM) or approximately 4 weeks from the end of initial radiochemotherapy. At the time of last assessment, 104 of the 120 patients had died.

**Treatment Paradigm**

Patients were treated with 60 Gy of external beam radiation therapy (2-Gy fractions given once daily for 5 days over a 6-week period) with concomitant TMZ (75 mg/m² orally or intravenously for 42 consecutive days), followed by a 28-day break and then adjuvant TMZ (150 mg/m² orally or intravenously for 5 consecutive days in the first 28-day cycle followed by 200 mg/m² orally or intravenously for 5 consecutive days in the first 28-day cycle for a maximum of 6 cycles). Diffusion and standard anatomical MRI were performed within 10 weeks after the start of RT + TMZ or within 4 weeks from the end of RT + TMZ—just before adjuvant TMZ (Figure 1). The beginning of adjuvant TMZ and the MRI evaluation were performed on the same day. This is typically the first imaging evaluation after completing RT + TMZ and is therefore an important clinical decision-making time point.

**MRI**

Diffusion and structural MRIs were obtained on a GE Signa Excite HDx or Lx 1.5T (GE Healthcare, Waukesha, WI); Siemens Avanto or Sonata 1.5T (Siemens Healthcare, Erlangen, Germany); or Siemens Trio, Allegra, or Verio 3T MRI system. Standard anatomical MRI consisted of pre- and postcontrast (gadolinium-diethylenetriamine pentacetic acid at a dose of 0.1 mmol/kg body weight; Magnevist, Bayer Schering Pharma, Leverkusen, Germany) axial T1-weighted images along with precontrast axial T2-weighted and fluid-attenuated inversion recovery sequences with standard sequence parameters. Patients

---

**Figure 1.** Treatment and MRI evaluation timeline. Patients were treated with 60 Gy of external beam radiation therapy (2-Gy fractions given once daily for 5 days over a 6-week period) with concomitant TMZ (75 mg/m² orally or intravenously for 42 consecutive days), followed by a 28-day break and then the start of adjuvant TMZ (150 mg/m² orally or intravenously for 5 consecutive days during the first 28-day cycle, followed by 200 mg/m² orally or intravenously for 5 consecutive days during the first 28-day cycle for a maximum of 6 cycles). Diffusion and standard anatomical MRI were performed within 10 weeks after the start of RT + TMZ or within 4 weeks from the end of RT + TMZ—just before adjuvant TMZ.
also received diffusion-weighted images with an echo/repetition time = 80 to 120 ms/>5000 ms, matrix size = 128 × 128, slice thickness = 3 mm with no interslice gap, and b values of 0 and 1000 s/mm² in 3 orthogonal directions. ADC maps were calculated for each image voxel as ADC(x, y, z) = −1/1000 · ln[S(x, y, z)/S₀(x, y, z)], where S(x, y, z) is the signal intensity of the voxel at coordinate (x, y, z) with b = 1000 s/mm² and S₀(x, y, z) is the signal intensity at voxel (x, y, z) with b = 0 s/mm².

**ADC Histogram Analysis**

ADC histogram analysis was performed using previously described techniques (13-15). Briefly, contrast-enhancing tumor regions were segmented on T1 subtraction images calculated by subtracting precontrast from postcontrast T1-weighted images (22). ADC characteristics from within enhancing regions were then extracted. A double Gaussian mixed model was used to describe the ADC histogram using nonlinear regression, where ADCH reflects the mean ADC in the larger of the two Gaussian distributions and ADCL is the mean ADC value of the lower Gaussian distribution (Figure 2). Both ADCL and ADCH were used as the primary imaging biomarker for the current study using GraphPad Prism version 6 (GraphPad Software, Inc., La Jolla, CA).

**Definition of Tumor Progression**

Progression was defined prospectively by the treating neuro-oncologists if subsequent scans showed an increase in imaging-evaluable tumor (≥25% increase in the sum of enhancing lesions, new enhancing lesions > 1 cm², an unequivocal qualitative increase in nonenhancing tumor, or an unequivocal new area of noncontrast-enhancing tumor). Patients were required to have a stable or decreasing contrast agent dose before partial or complete response could be determined. In addition, patients who required an increased dosage of steroids to maintain neurologic function, even when anatomical images showed no worsening, were considered to be stable but required early reevaluation. Patients who experienced significant neurologic decline were also declared to have progressed at the time of irreversible decline. Landmark PFS was defined as the time between the MRI scan following completion of RT + TMZ and progression. Landmark OS was defined as the time between the MRI scan and death.

**Statistical Analyses**

Receiver operating characteristic (ROC) analysis was used to determine whether a low ADCL could identify patients who progressed within 6 months from starting adjuvant TMZ (i.e., PFS6) and patients who died within 12 months from starting adjuvant TMZ (e.g., OS12) using area under the ROC curve (AUC) as a measure of performance. An ADCL value of 1.0 μm²/ms and ADCH value of 1.6 μm²/ms were chosen as the primary biomarkers of interest because these values were near the median of the patient distribution and found to have the highest likelihood ratio (sensitivity/[1 − specificity]) for both PFS6 and OS12. This cutoff was then used to stratify PFS and OS using both log-rank analysis on Kaplan-Meier data and multivariate Cox regression analysis using age as an additional covariate. A P value less than .05 was considered statistically significant, and a P value less than .10 was considered trending toward significance.

**RESULTS**

**ROC Analysis**

Results suggest ADCL is a significant predictor of patients that will progress within 6 months of starting adjuvant TMZ (Figure 3A; ROC AUC = 0.68 ± 0.053 SEM, P = .0011); however, ADCH was not a significant predictor of progression by 6 months (Figure 2A; ROC AUC = 0.5768 ± 0.057 SEM, P = .2187). A threshold of ADCL < 1.0 μm²/ms had a low sensitivity (34%) and high specificity (90%) for identifying patients that would progress within 6 months, meaning a high proportion of patients with low ADCL after RT + TMZ will progress early after starting adjuvant TMZ (Figure 3B; t test, P = .027). (For reference, an
ADCL also trended toward being a significant predictor of OS12 (Figure 3C; ROC AUC = 0.6176 ± 0.06551 SEM, P = .0547; ADCH; ROC AUC = 0.55 ± 0.064 SEM, P = .4104). ADCL showed a relatively low sensitivity (33%) but high specificity (82%) of predicting OS12 when using ADCL 1.2 m²/ms for patient stratification. (For ADCL 1.0 m²/ms, sensitivity/specificity = 73%/48%.)

Progression-Free Survival

Patients with an ADCL 1.0 μm²/ms had a significantly shorter PFS compared with the rest of the patients (Figure 4A; log-rank, P < .0001). Median PFS for patients exhibiting a low ADCL (< 1.0 μm²/ms) was 156 days compared with a median PFS of 288 days for patients with a high ADCL (> 1.0 μm²/ms). Similarly, patients with an ADCH 1.6 μm²/ms also demonstrated a significantly shorter PFS compared with the rest of the patients (Figure 4B; log-rank, P = .0012), with a median PFS of 173 days compared with 304 days for patients with an ADCH > 1.6 μm²/ms. A Cox multivariate regression that examined the effects of age, ADCL, and ADCH on PFS confirmed that ADCL was a significant predictor of PFS (Cox: HR = 0.11 [95% CI: 0.03, 0.39], P = .0006) and age trended toward significance (Cox: HR = 1.02 [95% CI: 1.00, 1.04], P = .0521). No association between ADCH and PFS was observed when accounting for age and ADCL (Cox regression, P = .9498). No differences in ADCL were observed between O6-methylguanine methyltransferase methylated and unmethylated tumors (t test, P = .38), but methylated tumors had significantly higher values of ADCH (t
Figure 4. Progression-free and overall survival. (A) Kaplan-Meier curves showing significantly lower PFS in patients with \( \text{ADC}_L < 1.0 \, \mu m^2/\text{ms} \) (log-rank, \( P < .0001 \); Cox multivariate, \( P = .0002 \)). (B) Kaplan-Meier curves showing significantly lower PFS in patients with \( \text{ADC}_H < 1.6 \, \mu m^2/\text{ms} \) in univariate analysis (log-rank, \( P = .0012 \)); however, \( \text{ADC}_H \) was not significant in multivariate analysis (Cox multivariate, \( P = .9498 \)). (C) Kaplan-Meier curves showing significantly lower OS in patients with \( \text{ADC}_L < 1.0 \, \mu m^2/\text{ms} \) (log-rank, \( P = .0002 \); Cox multivariate, \( P = .0487 \)). (D) Kaplan-Meier curves showing significantly lower OS in patients with \( \text{ADC}_H < 1.6 \, \mu m^2/\text{ms} \) in univariate analysis (log-rank, \( P = .0487 \)) but not when accounting for age and \( \text{ADC}_L \) (Cox multivariate, \( P = .5478 \)). (E) Kaplan-Meier curves showing differences in OS based on \( \text{ADC}_L \) higher or lower than 1.0 \( \mu m^2/\text{ms} \) for both bevacizumab-naïve (log-rank, \( P = .0130 \)) and bevacizumab-treated (log-rank, \( P = .0029 \)) patients at recurrence. No differences in OS were observed between patients treated with bevacizumab and those who were not within high \( \text{ADC}_L \) (log-rank, \( P = .1977 \)) or low \( \text{ADC}_L \) (log-rank, \( P = .8959 \)) groups. (F) Kaplan-Meier curves showing no differences in OS based on \( \text{ADC}_H \) higher or lower than 1.6 \( \mu m^2/\text{ms} \) for both bevacizumab-naïve (log-rank, \( P = .1330 \)) and bevacizumab-treated (log-rank, \( P = .1510 \)) patients at recurrence.
test, $P = .0443$; mean ADCl for methylated $= 1.50 \mu m^2/ms$; mean ADCl for unmethylated tumors $= 1.72 \mu m^2/ms$).

### Overall Survival

Patients with an ADCl $< 1.0 \mu m^2/ms$ had a significantly shorter OS compared with patients who had a higher ADCl (Figure 4C; log-rank, $P = .0002$), with median OS for patients with a low ADCl ($< 1.0 \mu m^2/ms$) around 407 days compared with 648 days for patients with a high ADCl ($> 1.0 \mu m^2/ms$). Similarly, patients with an ADCl $< 1.6 \mu m^2/ms$ also had a significantly shorter OS compared with patients who exhibited a higher ADCl (Figure 4D; log-rank, $P = .0487$), with median OS for patients with a low ADCl around 491 days compared with 662 days for patients with a high ADCl. Cox multivariate regression confirmed that both age (Cox: HR $= 1.03$ [95% CI: 1.01, 1.05], $P = .001$) and ADCl (Cox: HR $= 0.31$ [95% CI: 0.09, 0.98], $P = .047$) were correlated with OS. ADCl was not significantly associated with OS when accounting for age and ADCl (Cox, $P = .5478$).

Significant OS differences were observed between high and low ADCl in both patients who received bevacizumab at first recurrence ($n = 87$; log-rank, $P = .003$) and those who did not ($n = 33$; log-rank, $P = .01$) (Figure 4E). No differences were observed between high and low ADCl in patients who received bevacizumab at first recurrence (log-rank, $P = .1510$) and those who did not (log-rank, $P = .1330$) (Figure 4F). No differences in OS were observed between patients treated with bevacizumab and those who were not within high ADCl (log-rank, $P = .20$) or low ADCl (log-rank, $P = .90$) groups.

### DISCUSSION

Diffusion MRI measures of ADC have been shown to correlate with both tumor cellularity (19, 23–25) and mitotic activity (26). Therefore, successful radiochemotherapy would be expected to result in a relatively higher amount of tumor cell destruction, leading to an increase in the diffusivity of water within the tumor as a result of the lack of restrictions to diffusion from structures such as cell membranes. Tumors with a low ADC following combined RT + TMZ, on the other hand, may consist of a more cellular, aggressive, possibly more treatment-resistant tumor phenotype. Results from this study support this hypothesis, suggesting patients with an ADCl $< 1.0 \mu m^2/ms$ in contrast-enhancing tumors have a significantly shorter PFS and OS after starting adjuvant TMZ compared with other patients.

Previous studies using ADC histogram analysis have shown that tumor ADCl values greater than $1.2 \mu m^2/ms$ have a significantly longer PFS and OS in recurrent GBM treated with bevacizumab (13–15, 27). Using the threshold of $1.0 \mu m^2/ms$, we did not observe any difference in OS between patients treated with bevacizumab and those who were not. However, we did observe this trend at recurrence when using a threshold of $1.2 \mu m^2/ms$ (data not shown), but this threshold was not significant when used for evaluating adjuvant TMZ and thus was not used in this study. Together, these results may suggest patients with a low ADCl ($< 1.0 \mu m^2/ms$ after RT + TMZ are likely to be nonresponsive to any subsequent therapies, including bevacizumab or additional chemotherapies; patients with a high ADCl ($> 1.2 \mu m^2/ms$) are likely to respond favorably to bevacizumab at first recurrence; and patients with an intermediate ADCl ($1.0 \mu m^2/ms < ADCl < 1.2 \mu m^2/ms$) may benefit from subsequent chemotherapy before treatment with bevacizumab.

There are a few limitations to this study that should be noted. It is important to point out that there was a potential selection bias because only patients who successfully completed surgical resection and RT + TMZ with a measurable contrast-enhancing tumor ($> 0.1 cc$) were eligible for ADC histogram analysis. In addition, it is conceivable that some patients determined to have early progression after completing RT + TMZ actually had pseudoprogression, or treatment-related changes in vascular permeability that mimic radiographic changes similar to treatment failure or tumor growth. The addition of multimodal imaging techniques, including perfusion MRI (28), may have allowed for a more accurate delineation of pseudoprogression from true progression. Despite this potential confounding variable, we found significant differences in both PFS and OS in all patients based on diffusion characteristics as well as in patients with a PFS greater than 3 months from the end of RT + TMZ, where the incidence of pseudoprogression is likely to be highest. Moreover, this study involved acquiring diffusion MRIs using a variety of MRI systems and field strengths for the purpose of mimicking a clinical trial environment. Recent studies have shown that errors in ADC measurements vary nonlinearly from the scanner isocenter and that different MRI systems have different degrees of nonlinearity (29). Thus, this study would have benefited from the use of a temperature-controlled water phantom to account for system-specific errors in ADC measurements.

In summary, this study demonstrates that diffusion characteristics obtained using ADC histogram analysis can be used to predict PFS and OS after completing RT + TMZ and before adjuvant TMZ therapy. Results suggest that patients with an ADCl $< 1.0 \mu m^2/ms$ are at increased risk for early progression and early death, indicating that ADC histogram analysis may be useful for patient-risk stratification after completing RT + TMZ. Future studies aimed at integrating ADC histogram analysis into clinical decision making as well as identifying biological correlates of diffusion characteristics are warranted.

### Conflicts of Interest

Drs. Timothy F. Cloughesy, Albert Lai, Whitney B. Pope, and Benjamin M. Ellingson are paid consultants for Genentech, Inc., and Hoffman-La Roche, Ltd. Drs. Ellingson and Pope are also a paid consultant for MedQIA, LLC.
REFERENCES

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mimi-mann RO. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.

2. Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. J Neurooncol. 2013;112(2):277–283.

3. Sher DJ, Henson JW, Avuto B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008;88(1):43–50.

4. Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K, Komorat RJ. Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest. 2013;31(5):287–308.

5. Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R, Kumar V, Goyal MM, Chaurasia S, Shetty R, Gopal AK. Molecular profiling and survival analysis of glioblastomas. J Neurooncol. 2008;85(2):169–178.

6. Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma multiforme: advancements from the last quarter century. Cancer Invest. 2013;31(5):287–308.

7. Mazaris P, Hong X, Altshuler D, Schultz L, Poisson LM, Jain R, Mikkelsen T, Njoliu J, Weng Y, Wang K, Bathurst R, Loo Y, Saudan P, Pegram J, Mikkelsen TS, Jordan P, Xiao J, Mikkelsen TD, Jain R, Buchhalter A. The added value of concurrently administered temozolomide during radiotherapy for newly diagnosed glioblastoma. J Neurooncol. 2008;89(1):15–26.

8. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Cloughesy TF, Huffman ER, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF. Diffusion MRI Predicts Survival in Glioblastoma. J Neurooncol. 2009;92(2):177–185.

9. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gabbai FS, Fan X, Tsien CI, Lawrence TS, Junck LR, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005;102(46):16759–16764.

10. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalaezari S, Wagle N, Naeini KM, Carroll J, Liu AM, Pope WB. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012;14(1):333–343.

11. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gabbai FS, Fan X, Tsien CI, Lawrence TS, Junck LR, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005;102(46):16759–16764.

12. Chenevert TL, Stegman JD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029–2036.

13. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol. 2004;25(2):201–209.

14. Castillo M, Smith JK, Kwock L, Wilber K. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol. 2001;22(1):60–64.

15. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014;271(1):200–210.

16. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaVerda BV, Decker DP, Schminade KM. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538–548.

17. Glinka A, Togari K, Yachi M, Ishikawa S, Shimogata Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 2010;31(3):538–548.

18. Senghore A, Higuchi T, Tojo Y, Kichi M, Inokuma S, Shimada T, Ito K, Kajiyama R, Takahashi M. Diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 2010;31(3):538–548.

19. Khorasan A, O’Dowd D, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF. Diffusion MRI Predicts Survival in Glioblastoma. J Neurooncol. 2009;92(2):177–185.

20. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter SE, Watson JD, Wang J, Atkins JN, Weng Y, Liu J, Kim S, Pohl BA, Nelson SF, Karpova E, Delbeck J, Wang X, Lawlor E, Chenevert TL, and the Conformal Radiotherapy Collaborative Study Group. Demonstration of nonlinearity bias in the measurement of the apparent diffusion coefficient in multicenter trials. [epub ahead of print]. Magn Reson Med. 2010.1002/mm.25754.